Nitasha Sarswat to Amyloid Neuropathies, Familial
This is a "connection" page, showing publications Nitasha Sarswat has written about Amyloid Neuropathies, Familial.
Connection Strength
2.049
-
Impact of Tafamidis on Survival in a Real-World Community-Based Cohort. Curr Probl Cardiol. 2022 Dec; 47(12):101358.
Score: 0.737
-
Disparities in diagnosis and outcomes in American patients with transthyretin cardiac amyloidosis. Int J Cardiovasc Imaging. 2025 Aug; 41(8):1487-1496.
Score: 0.224
-
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy. J Am Coll Cardiol. 2025 May 27; 85(20):1911-1923.
Score: 0.223
-
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Circulation. 2025 Mar 04; 151(9):601-611.
Score: 0.215
-
99m Technetium-pyrophosphate bone scan: A potential biomarker for the burden of transthyretin amyloidosis in skeletal muscle: A preliminary study. Muscle Nerve. 2023 Feb; 67(2):111-116.
Score: 0.187
-
Progressive Multiple Mononeuropathy in a Patient With Familial Transthyretin Amyloidosis After Liver Transplantation. J Clin Neuromuscul Dis. 2022 Mar 01; 23(3):143-147.
Score: 0.178
-
Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression. Orphanet J Rare Dis. 2021 10 03; 16(1):411.
Score: 0.174
-
Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool. Eur Heart J. 2025 10 22; 46(40):4090-4101.
Score: 0.057
-
Defining echocardiographic predictors of outcome in cardiac amyloidosis by subtype. Curr Probl Cardiol. 2024 Sep; 49(9):102729.
Score: 0.052